Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. - Wikidata - awgldk - TriplyDB

Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

http://www.wikidata.org/entity/Q33895725

about

Identification of a novel 'aggregation-prone'/'amyloidogenic determinant' peptide in the sequence of the highly amyloidogenic human calcitonin Early implementation of QbD in biopharmaceutical development: a practical example Three-Dimensional Structure and Orientation of Rat Islet Amyloid Polypeptide Protein in a Membrane Environment by Solution NMR Spectroscopy Converting the Highly Amyloidogenic Human Calcitonin into a Powerful Fibril Inhibitor by Three-dimensional Structure Homology with a Non-amyloidogenic Analogue Chimeric Glutathione S-Transferases Containing Inserts of Kininogen Peptides: POTENTIAL NOVEL PROTEIN THERAPEUTICS Amyloid as a depot for the formulation of long-acting drugs AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides.Engineering the isobutanol biosynthetic pathway in Escherichia coli by comparison of three aldehyde reductase/alcohol dehydrogenase genes.Therapeutic protein aggregation: mechanisms, design, and control.The amyloid stretch hypothesis: recruiting proteins toward the dark side Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis NMR investigations of structural and dynamics features of natively unstructured drug peptide - salmon calcitonin: implication to rational design of potent sCT analogs.Human pancreatitis-associated protein forms fibrillar aggregates with a native-like conformation.Rational development of a strategy for modifying the aggregatibility of proteins.Alternative computational protocols for supercharging protein surfaces for reversible unfolding and retention of stability Rational improvement of simvastatin synthase solubility in Escherichia coli leads to higher whole-cell biocatalytic activity.Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass Toward a molecular understanding of protein solubility: increased negative surface charge correlates with increased solubility TANGO-Inspired Design of Anti-Amyloid Cyclic Peptides.NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG.All-atom molecular dynamics analysis of multi-peptide systems reproduces peptide solubility in line with experimental observations Protein aggregation in silico.Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa.Computational approaches to understanding protein aggregation in neurodegeneration.Molecular understanding of a potential functional link between antimicrobial and amyloid peptides.Growth-incompetent monomers of human calcitonin lead to a non-canonical direct relationship between peptide concentration and lag time.Supercharging proteins can impart unusual resilience.Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy.Interpretation of the dissolution of insoluble peptide sequences based on the acid-base properties of the solvent.Structure-based engineering of a monoclonal antibody for improved solubility.Functional characteristics of small proteins (70 amino acid residues) forming protein-nucleic acid complexes.Measurement of calcitonin by immunoassay analyzers.An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers.A dimer model of human calcitonin13-32 forms an α-helical structure and robustly aggregates in 50% aqueous 2,2,2-trifluoroethanol solution.

P2860

Q24315813-09B68544-085F-4178-B736-CC40848A36A3 Q26830466-CE145BC2-2E0C-44AC-9408-DFABF131B073 Q27655538-EAB53FDF-C331-41D8-8B66-4416BBB2B67C Q27665898-F923D621-33EC-49AA-81A7-9BA866DB0D3B Q27679018-4015753E-CABC-40BD-9EA7-B26A5575F079 Q28472154-7482F13A-B6A4-4232-80D3-30439E1C168F Q33275645-28940590-DAB2-480D-B467-02E2C82CAEF7 Q33574975-B1A3BFEC-F320-4042-9A41-60BD3F2C69D6 Q34097620-D82CC15D-E8A6-4902-ADF8-28C2F77E52BA Q34133256-0BD1362F-F8EB-44ED-8833-27969615D8D5 Q34478940-60A9CF54-536F-43A7-BE74-78E462480C0F Q34499176-723B9DE0-EE85-4A5F-B7E7-1CF989CF7069 Q34564980-A360E5E8-D866-460F-B875-3E59CB2BCF01 Q34694133-487193AD-D288-4983-88B2-F3B6C31FD0F8 Q34760462-30094F28-81CC-4E3E-B2BE-2257629E1B05 Q34873985-AD688700-14D3-44F9-9C70-1C94D72BF6D9 Q35840489-D3C17D41-B0B0-4D4C-974A-F4BBE493D143 Q35895112-C82BFA7E-9C20-435F-8ADE-174A3935CE5B Q36062167-9ED50137-3B02-4571-86A8-FA5C4185D060 Q36118412-7ED768CF-D0CC-4F2F-B1C8-9696F3199C1E Q36512184-AFB15B43-FF98-4B2A-9AAD-2679DBAA901D Q36791404-6366B398-5716-473A-9847-17F45B908E04 Q37407693-81792884-58DA-4674-B676-67894C13A9F9 Q37715960-7ABE8582-64CA-4108-84D1-F2C6FE6948FF Q38238202-3F3CA8E6-F686-4559-ABD7-6ED9F16E66F2 Q38652444-A7D471A4-7D2E-4F72-A716-5B70014ED0C8 Q39273315-F56F2AAC-748C-4C0F-9A89-5D3313C26E81 Q42720704-46A13D74-F482-48F6-956C-C18F54EDAA95 Q43043676-5B37D4B1-9ECE-4161-8A03-997C2F33BCDF Q44381771-F6E29F25-BFF4-44E9-B783-E384A0C2C976 Q47963918-887BC4EF-4D29-4604-A235-86DFA9078BC2 Q51010485-762E364D-D434-41CE-93CC-23240B3B4806 Q53006025-6BEA28D4-778A-4F1F-BB0C-C8603A0C636F Q54011312-32BFDC58-47B8-4352-8974-0884638F263C

P2860

Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.

http://www.wikidata.org/entity/Q33895725

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Rational design of aggregation ...... eengineering human calcitonin.

@ast

Rational design of aggregation ...... eengineering human calcitonin.

@en

type

label

Rational design of aggregation ...... eengineering human calcitonin.

@ast

Rational design of aggregation ...... eengineering human calcitonin.

@en

prefLabel

Rational design of aggregation ...... eengineering human calcitonin.

@ast

Rational design of aggregation ...... eengineering human calcitonin.

@en

P1433

Q33895725-49C2DAD9-123F-4DBE-8732-7F437AC7E191

P1476

Q33895725-144BED9D-B040-4454-A9DA-050C5397CCEA

P2093

Q33895725-0B604510-4E45-4730-9BCC-6340D025CB40

Q33895725-89C981D1-8613-4D82-A2CD-3BE7B9748839

Q33895725-9043CEE0-4E9F-4A9B-A05E-2FC60B011941

Q33895725-9BEFE3DB-D828-43C9-B490-8EF73438A783

Q33895725-AC25C490-D23A-4C59-8418-3C9E649F1986

P2860

Q33895725-077A2DFC-F056-4A9B-B72E-44BB3A27F398

Q33895725-0D27573A-3846-41BA-B89C-9A06835CD80C

Q33895725-12AEE823-10BE-46F4-A232-40FD78EA901A

Q33895725-1352587B-7F8E-4185-BF43-8B2A531091B2

Q33895725-16EA8892-859B-4039-A699-7638DF0715B1

Q33895725-1AECF49E-6D24-4EED-89C3-3D0B00DBB758

Q33895725-1F403449-D904-4411-8AA0-D54C26504DE2

Q33895725-23181488-5870-403A-8A44-DE54A49FEC6D

Q33895725-2361E235-C822-45C0-B92F-EE05B276D0BF

Q33895725-23CD02A2-4840-47A2-A5DD-B8415171B77F

P304

Q33895725-D1A30699-16FB-46F5-B0D8-8F1502D5739F

P31

Q33895725-DFFFF00E-B77A-4D18-9961-4E26E0BC5E4C

P356

Q33895725-55ACF5C4-0496-4112-92DE-1A577970351E

P407

Q33895725-D97D7B84-80C2-46E1-8A72-E7F1A4456B19

P433

Q33895725-5692B720-AFDF-4F79-8201-1B46CF489171

P478

Q33895725-D938E3B8-D5D1-4922-BB9F-62018B1E545C

P50

Q33895725-4FF62668-7D26-4E1F-B987-0CB6297C4342

P577

Q33895725-10545EB8-20DC-4938-9CDF-5D6BAD4DCE0E

P5875

Q33895725-2B22B5D0-C9DD-4450-AE08-765761735937

P698

Q33895725-968A77F3-D60E-4B75-B6FE-7D76FB6A8495

P932

Q33895725-5736C729-0CA8-46F6-BD81-4BF2449B3220

P356

PNAS.0501215102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Rational design of aggregation ...... eengineering human calcitonin.

@en

P2093

Fabrizio Chiti

http://www.w3.org/2001/XMLSchema#string

Jesús Zurdo

http://www.w3.org/2001/XMLSchema#string

Roman Muff

http://www.w3.org/2001/XMLSchema#string

Stephen Poon

http://www.w3.org/2001/XMLSchema#string

Susan B Fowler

http://www.w3.org/2001/XMLSchema#string

P2860

Calcitonin receptor mRNA in mononuclear leucocytes from postmenopausal women: decrease during osteoporosis and link to bone markers with specific isoform involvement

International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

Preparation of iodine-131 labelled human growth hormone of high specific activity

Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case.

Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain.

Nature disfavors sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis.

Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane.

Rationalization of the effects of mutations on peptide and protein aggregation rates.

A highly amyloidogenic region of hen lysozyme.

P304

10105-10110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0501215102

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7737095

http://www.w3.org/2001/XMLSchema#string

P698

16006528

http://www.w3.org/2001/XMLSchema#string

P932

1174920

http://www.w3.org/2001/XMLSchema#string